Last Updated: October 1, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

China: These 47 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Generic Entry Dates in Other Countries

African Regional IP Organization (ARIPO) Argentina Australia Austria Brazil Canada Chile Colombia Costa Rica Croatia Cuba Cyprus Denmark Dominican Republic Ecuador Eurasian Patent Organization European Patent Office Finland France Georgia, Republic of Germany Guatemala Honduras Hong Kong Hungary Israel Italy Japan Jordan Lithuania Luxembourg Malaysia Mexico Montenegro Morocco Netherlands New Zealand Nicaragua Norway Panama Peru Philippines Poland Portugal Russian Federation San Marino Saudi Arabia Serbia Singapore Slovenia South Africa South Korea Spain Taiwan Tunisia Turkey Ukraine United Kingdom United States Uruguay
Preferred citation:
Friedman, Yali, "China: These 47 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can TYMLOS (abaloparatide) generic drug versions launch in China?

Generic name: abaloparatide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2026
Generic Entry Controlled by: China Patent 101,578,093
Patent Title: Method of drug delivery for bone anabolic protein

Drug Price Trends for TYMLOS
TYMLOS is a drug marketed by Radius. There are nine patents protecting this drug. There has been litigation on patents covering TYMLOS

See drug price trends for TYMLOS.

The generic ingredient in TYMLOS is abaloparatide. Additional details are available on the abaloparatide profile page.

When can TYMLOS (abaloparatide) generic drug versions launch in China?

Generic name: abaloparatide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2026
Generic Entry Controlled by: China Patent 102,274,492
Patent Title: Delivery method of bone anabolic protein drug

Drug Price Trends for TYMLOS
TYMLOS is a drug marketed by Radius. There are nine patents protecting this drug. There has been litigation on patents covering TYMLOS

See drug price trends for TYMLOS.

The generic ingredient in TYMLOS is abaloparatide. Additional details are available on the abaloparatide profile page.

When can COTELLIC (cobimetinib fumarate) generic drug versions launch in China?

Generic name: cobimetinib fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 05, 2026
Generic Entry Controlled by: China Patent 101,365,676

COTELLIC is a drug marketed by Genentech Inc. There are seven patents protecting this drug.

See drug price trends for COTELLIC.

The generic ingredient in COTELLIC is cobimetinib fumarate. Additional details are available on the cobimetinib fumarate profile page.

When can COTELLIC (cobimetinib fumarate) generic drug versions launch in China?

Generic name: cobimetinib fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 05, 2026
Generic Entry Controlled by: China Patent 103,524,392

COTELLIC is a drug marketed by Genentech Inc. There are seven patents protecting this drug.

See drug price trends for COTELLIC.

The generic ingredient in COTELLIC is cobimetinib fumarate. Additional details are available on the cobimetinib fumarate profile page.

When can COTELLIC (cobimetinib fumarate) generic drug versions launch in China?

Generic name: cobimetinib fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 05, 2026
Generic Entry Controlled by: China Patent 104,892,582

COTELLIC is a drug marketed by Genentech Inc. There are seven patents protecting this drug.

See drug price trends for COTELLIC.

The generic ingredient in COTELLIC is cobimetinib fumarate. Additional details are available on the cobimetinib fumarate profile page.

When can COTELLIC (cobimetinib fumarate) generic drug versions launch in China?

Generic name: cobimetinib fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 05, 2026
Generic Entry Controlled by: China Patent 109,053,523

COTELLIC is a drug marketed by Genentech Inc. There are seven patents protecting this drug.

See drug price trends for COTELLIC.

The generic ingredient in COTELLIC is cobimetinib fumarate. Additional details are available on the cobimetinib fumarate profile page.

When can COTELLIC (cobimetinib fumarate) generic drug versions launch in China?

Generic name: cobimetinib fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 05, 2026
Generic Entry Controlled by: China Patent 110,668,988

COTELLIC is a drug marketed by Genentech Inc. There are seven patents protecting this drug.

See drug price trends for COTELLIC.

The generic ingredient in COTELLIC is cobimetinib fumarate. Additional details are available on the cobimetinib fumarate profile page.

When can BEVYXXA (betrixaban) generic drug versions launch in China?

Generic name: betrixaban
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2026
Generic Entry Controlled by: China Patent 101,304,971
Patent Title: Pharmaceutical salts and polymorphs of n- (5-chl0r0-2-pyridinyl) -2- [ [4- [ (dimethylamino) iminomethyl] benzoyl] amino] -5-meth oxy-benzamide, a factor xa inhibitor

BEVYXXA is a drug marketed by Portola Pharms Inc. There are five patents protecting this drug. There has been litigation on patents covering BEVYXXA

See drug price trends for BEVYXXA.

The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.

When can ENTRESTO SPRINKLE (sacubitril; valsartan) generic drug versions launch in China?

Generic name: sacubitril; valsartan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: China Patent 102,702,119
Patent Title: Pharmaceutical combinations of an angiotensin receptor antagonist and an NEP inhibitor

Drug Price Trends for ENTRESTO SPRINKLE
ENTRESTO SPRINKLE is a drug marketed by Novartis. There are three patents protecting this drug. There has been litigation on patents covering ENTRESTO SPRINKLE

See drug price trends for ENTRESTO SPRINKLE.

The generic ingredient in ENTRESTO SPRINKLE is sacubitril; valsartan. Additional details are available on the sacubitril; valsartan profile page.

When can PYLARIFY (piflufolastat f-18) generic drug versions launch in China?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: China Patent 101,778,910

PYLARIFY is a drug marketed by Progenics Pharms Inc and AphelionThere are six patents protecting this drug.

See drug price trends for PYLARIFY.

The generic ingredient in PYLARIFY is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can PYLARIFY (piflufolastat f-18) generic drug versions launch in China?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: China Patent 103,922,998

PYLARIFY is a drug marketed by Progenics Pharms Inc and AphelionThere are six patents protecting this drug.

See drug price trends for PYLARIFY.

The generic ingredient in PYLARIFY is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can PYLARIFY TRUVU (piflufolastat f-18) generic drug versions launch in China?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: China Patent 101,778,910

PYLARIFY TRUVU is a drug marketed by Aphelion. There are six patents protecting this drug.

The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can PYLARIFY TRUVU (piflufolastat f-18) generic drug versions launch in China?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: China Patent 103,922,998

PYLARIFY TRUVU is a drug marketed by Aphelion. There are six patents protecting this drug.

The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can KORSUVA (difelikefalin acetate) generic drug versions launch in China?

Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: China Patent 101,535,336

KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug. There has been litigation on patents covering KORSUVA

See drug price trends for KORSUVA.

The generic ingredient in KORSUVA is difelikefalin acetate. Additional details are available on the difelikefalin acetate profile page.

When can KORSUVA (difelikefalin acetate) generic drug versions launch in China?

Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: China Patent 101,627,049

KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug. There has been litigation on patents covering KORSUVA

See drug price trends for KORSUVA.

The generic ingredient in KORSUVA is difelikefalin acetate. Additional details are available on the difelikefalin acetate profile page.

When can ZTALMY (ganaxolone) generic drug versions launch in China?

Generic name: ganaxolone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: China Patent 106,667,918

ZTALMY is a drug marketed by Immedica Pharma. There are eleven patents protecting this drug. There has been litigation on patents covering ZTALMY

See drug price trends for ZTALMY.

The generic ingredient in ZTALMY is ganaxolone. Additional details are available on the ganaxolone profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in China?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: China Patent 101,547,904

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in China?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: China Patent 105,012,303

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in China?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: China Patent 101,616,895

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in China?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: China Patent 102,317,268

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in China?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: China Patent 103,641,833

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in China?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: China Patent 101,389,338

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can EPSOLAY (benzoyl peroxide) generic drug versions launch in China?

Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: China Patent 101,754,677
Patent Title: Method for preparing particles comprising metal oxide coating and particles with metal oxide coating

Drug Price Trends for EPSOLAY
EPSOLAY is a drug marketed by Mayne Pharma. There are fourteen patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering EPSOLAY

See drug price trends for EPSOLAY.

The generic ingredient in EPSOLAY is benzoyl peroxide. Additional details are available on the benzoyl peroxide profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in China?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: China Patent 101,646,420

Drug Price Trends for OSENI
OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can LEXISCAN (regadenoson) generic drug versions launch in China?

Generic name: regadenoson
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 02, 2027
Generic Entry Controlled by: China Patent 101,379,073
Patent Title: Process for preparing an a2a-adenosine receptor agonist and its polymorphs

LEXISCAN is a drug marketed by Astellas. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering LEXISCAN

See drug price trends for LEXISCAN.

The generic ingredient in LEXISCAN is regadenoson. Additional details are available on the regadenoson profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in China?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: China Patent 101,686,943

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in China?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: China Patent 103,933,555

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in China?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: China Patent 101,686,943

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in China?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: China Patent 103,933,555

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can SPRAVATO (esketamine hydrochloride) generic drug versions launch in China?

Generic name: esketamine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: China Patent 101,466,364
Patent Title: Intranasal administration of ketamine to treat depression

Drug Price Trends for SPRAVATO
SPRAVATO is a drug marketed by Janssen Pharms. There are seven patents protecting this drug. There has been litigation on patents covering SPRAVATO

See drug price trends for SPRAVATO.

The generic ingredient in SPRAVATO is esketamine hydrochloride. Additional details are available on the esketamine hydrochloride profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in China?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: China Patent 101,668,738

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in China?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: China Patent 104,211,624

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can VARUBI (rolapitant hydrochloride) generic drug versions launch in China?

Generic name: rolapitant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 04, 2027
Generic Entry Controlled by: China Patent 102,276,606

VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.

The generic ingredient in VARUBI is rolapitant hydrochloride. Additional details are available on the rolapitant hydrochloride profile page.

When can INLYTA (axitinib) generic drug versions launch in China?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: China Patent 101,679,356

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can INLYTA (axitinib) generic drug versions launch in China?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: China Patent 103,626,739

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in China?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: China Patent 101,460,489
Patent Title: Modulators of atp-binding cassette transporters

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in China?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: China Patent 103,254,177
Patent Title: Modulators of atp-binding cassette transporters

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can QVAR REDIHALER (beclomethasone dipropionate) generic drug versions launch in China?

Generic name: beclomethasone dipropionate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 11, 2027
Generic Entry Controlled by: China Patent 101,657,829

Drug Price Trends for QVAR REDIHALER
QVAR REDIHALER is a drug marketed by Norton Waterford. There are seventeen patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering QVAR REDIHALER

See drug price trends for QVAR REDIHALER.

The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. Additional details are available on the beclomethasone dipropionate profile page.

When can TRADJENTA (linagliptin) generic drug versions launch in China?

Generic name: linagliptin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 30, 2027
Generic Entry Controlled by: China Patent 101,437,493

Drug Price Trends for TRADJENTA
TRADJENTA is a drug marketed by Boehringer Ingelheim. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market. There has been litigation on patents covering TRADJENTA

See drug price trends for TRADJENTA.

The generic ingredient in TRADJENTA is linagliptin. Additional details are available on the linagliptin profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in China?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: China Patent 101,686,930

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in China?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: China Patent 102,688,207

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in China?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: China Patent 102,697,745

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in China?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: China Patent 101,490,053

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in China?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: China Patent 103,435,595

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in China?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: China Patent 103,467,385

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in China?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: China Patent 101,679,315

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in China?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: China Patent 101,677,965

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in China?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: China Patent 101,677,959

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in China?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: China Patent 101,677,959

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in China?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: China Patent 101,932,582

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in China?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: China Patent 103,524,509

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can TRINTELLIX (vortioxetine hydrobromide) generic drug versions launch in China?

Generic name: vortioxetine hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 15, 2027
Generic Entry Controlled by: China Patent 102,614,179
Patent Title: 1- [2- (2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment

Drug Price Trends for TRINTELLIX
TRINTELLIX is a drug marketed by Takeda Pharms Usa. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market. There has been litigation on patents covering TRINTELLIX

See drug price trends for TRINTELLIX.

The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. Additional details are available on the vortioxetine hydrobromide profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in China?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: China Patent 101,711,254
Patent Title: Synthetic bile acid composition, method, and preparation

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in China?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: China Patent 106,083,969
Patent Title: 合成胆汁酸组合物、方法和制剂 (Synthetic bile acid composition, method, and preparation)

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in China?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: China Patent 106,146,594
Patent Title: 合成胆汁酸组合物、方法和制剂 (Synthetic bile acid composition, method, and preparation)

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in China?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: China Patent 108,191,940
Patent Title: 合成胆汁酸组合物、方法和制剂 (Synthetic bile acid composition, method, and preparation)

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in China?

Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: China Patent 101,501,019
Patent Title: Short-acting benzodiazepine salts and their polymorphic forms

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in China?

Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: China Patent 103,288,834
Patent Title: Short-acting benzodiazepine salts and their polymorphic forms

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in China?

Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: China Patent 104,059,071
Patent Title: Short-acting Benzodiazepine Salts And Their Polymorphic Forms

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in China?

Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: China Patent 104,059,072
Patent Title: Short-acting Benzodiazepine Salts And Their Polymorphic Forms

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

When can EPIDUO (adapalene; benzoyl peroxide) generic drug versions launch in China?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: China Patent 101,541,320
Patent Title: Combination of adapalene and benzoyl peroxide for treating acne lesions

Drug Price Trends for EPIDUO
EPIDUO is a drug marketed by Galderma Labs Lp and Galderma LabsThere are three patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering EPIDUO

See drug price trends for EPIDUO.

The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can EPIDUO FORTE (adapalene; benzoyl peroxide) generic drug versions launch in China?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: China Patent 101,541,320
Patent Title: Combination of adapalene and benzoyl peroxide for treating acne lesions

Drug Price Trends for EPIDUO FORTE
EPIDUO FORTE is a drug marketed by Galderma Labs. There has been litigation on patents covering EPIDUO FORTE

See drug price trends for EPIDUO FORTE.

The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in China?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: China Patent 101,687,857
Patent Title: Pyridazinone derivates

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in China?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: China Patent 101,743,241
Patent Title: Pyridazinone derivates

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can KAZANO (alogliptin benzoate; metformin hydrochloride) generic drug versions launch in China?

Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 19, 2027
Generic Entry Controlled by: China Patent 101,801,351

Drug Price Trends for KAZANO
KAZANO is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KAZANO

See drug price trends for KAZANO.

The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.

When can WINLEVI (clascoterone) generic drug versions launch in China?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: China Patent 101,743,316

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are eight patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in China?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: China Patent 103,450,304

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are eight patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in China?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: China Patent 104,861,023

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are eight patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can INTRAROSA (prasterone) generic drug versions launch in China?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: China Patent 101,861,152
Patent Title: DEHA compositions for treating menopause

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can INTRAROSA (prasterone) generic drug versions launch in China?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: China Patent 102,861,335
Patent Title: DHEA compositions for treating menopause

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can INTRAROSA (prasterone) generic drug versions launch in China?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: China Patent 105,412,121
Patent Title: DHEA compositions for treating menopause

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can INTRAROSA (prasterone) generic drug versions launch in China?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: China Patent 109,893,526
Patent Title: 治疗绝经期的DEHA组合物 (DHEA compositions for treating menopause)

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can LOCAMETZ (gallium ga-68 gozetotide) generic drug versions launch in China?

Generic name: gallium ga-68 gozetotide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 17, 2027
Generic Entry Controlled by: China Patent 102,014,956

LOCAMETZ is a drug marketed by Novartis. There are two patents protecting this drug.

See drug price trends for LOCAMETZ.

The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. Additional details are available on the gallium ga-68 gozetotide profile page.

When can LOCAMETZ (gallium ga-68 gozetotide) generic drug versions launch in China?

Generic name: gallium ga-68 gozetotide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 17, 2027
Generic Entry Controlled by: China Patent 104,873,982

LOCAMETZ is a drug marketed by Novartis. There are two patents protecting this drug.

See drug price trends for LOCAMETZ.

The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. Additional details are available on the gallium ga-68 gozetotide profile page.

When can PREPOPIK (citric acid; magnesium oxide; sodium picosulfate) generic drug versions launch in China?

Generic name: citric acid; magnesium oxide; sodium picosulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 12, 2027
Generic Entry Controlled by: China Patent 101,406,457

PREPOPIK is a drug marketed by Ferring Pharms Inc. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PREPOPIK

See drug price trends for PREPOPIK.

The generic ingredient in PREPOPIK is citric acid; magnesium oxide; sodium picosulfate. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.

When can PREPOPIK (citric acid; magnesium oxide; sodium picosulfate) generic drug versions launch in China?

Generic name: citric acid; magnesium oxide; sodium picosulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 12, 2027
Generic Entry Controlled by: China Patent 101,820,859

PREPOPIK is a drug marketed by Ferring Pharms Inc. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PREPOPIK

See drug price trends for PREPOPIK.

The generic ingredient in PREPOPIK is citric acid; magnesium oxide; sodium picosulfate. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in China?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: China Patent 104,688,702
Patent Title: PHARMACEUTICAL COMPOSITIONS

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in China?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: China Patent 111,789,820
Patent Title: 药物组合物 (PHARMACEUTICAL COMPOSITIONS)

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in China?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: China Patent 112,022,821
Patent Title: 药物组合物 (Pharmaceutical compositions)

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in China?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2027
Generic Entry Controlled by: China Patent 103,641,816

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZEMDRI (plazomicin sulfate) generic drug versions launch in China?

Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 21, 2027
Generic Entry Controlled by: China Patent 101,868,472
Patent Title: Antibacterial aminoglycoside analogs

ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug. There has been litigation on patents covering ZEMDRI

See drug price trends for ZEMDRI.

The generic ingredient in ZEMDRI is plazomicin sulfate. Additional details are available on the plazomicin sulfate profile page.

When can ZEMDRI (plazomicin sulfate) generic drug versions launch in China?

Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 21, 2027
Generic Entry Controlled by: China Patent 103,360,440
Patent Title: 抗菌性氨基糖苷类似物 (Antibacterial aminoglycoside analogs)

ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug. There has been litigation on patents covering ZEMDRI

See drug price trends for ZEMDRI.

The generic ingredient in ZEMDRI is plazomicin sulfate. Additional details are available on the plazomicin sulfate profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in China?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: China Patent 102,186,827

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in China?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: China Patent 102,186,832

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in China?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: China Patent 102,643,241

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in China?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: China Patent 103,058,944

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in China?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: China Patent 103,819,419

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in China?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: China Patent 102,186,827

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in China?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: China Patent 102,186,832

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in China?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: China Patent 102,643,241

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in China?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: China Patent 103,058,944

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in China?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: China Patent 103,819,419

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

Last updated: May 12, 2026

China Branded and Generic Drug Markets Assessment, Regulatory Opportunities, Challenges, and Patent/Exclusivity Risks

China’s branded and generic medicines market is large, fast-growing, and structurally shaped by centralized procurement (VBP), NRDL access, and an evolving IP enforcement and registration framework. Branded leaders face revenue compression from bid-based price cuts, channel leverage from centralized tenders, and tighter label and prescribing dynamics. Generic entrants face accelerated competition but must clear bioequivalence, patent and exclusivity barriers, and jurisdiction-specific regulatory scrutiny under NMPA. The main regulatory opportunities cluster around (1) clinical development optimization for China-specific approvals, (2) lifecycle management strategies that withstand patent challenges, and (3) contract and manufacturing partnerships aligned to NMPA expectations for consistency, validation, and quality systems.

How big are China’s branded vs generic drug markets, and what’s driving volume vs price?

China’s drug market is dominated by volume growth and policy-driven price declines. Branded revenue typically erodes faster than volume as VBP expands, while generics gain share through procurement wins and NRDL listings.

Key structural forces affecting branded pricing

  • Centralized volume-based procurement (VBP) and negotiated price ceilings: branded products often lose tender share when generics win or when price caps tighten.
  • NRDL listings and access pathways: branded launches that secure NRDL can command initial volume, but follow-on competition and periodic price negotiations can reduce net revenue per unit.
  • Reimbursement dynamics: provincial formularies and hospital formularies increasingly align to national reimbursement lists, limiting protected territory for brands.

Key structural forces affecting generic adoption

  • ME-bioequivalence expectations: generics compete on BE, manufacturing, and dossier quality.
  • Consistent manufacturing and comparability: regulators scrutinize process control, impurity profiles, and batch-to-batch comparability.
  • Procurement economics: generics can scale rapidly after procurement success, turning regulatory “approval” into commercial “access.”

What regulatory pathways does NMPA use for branded and generic drug approval?

China’s registration system provides multiple tracks that can materially change timelines and probability of approval for branded and generic products.

Core NMPA approval tracks

  • New Drug Application (NDA) for innovative drugs: clinical dataset requirements and CMC validation are central.
  • Generic drug registration: BE studies and quality comparability are key, with waivers possible for specific drug classes or clinical/analytical justifications.
  • Supplementary applications: line extensions (new indication, new dosage form, new strength) and CMC changes.

BE and quality standards

  • Generic approval is typically contingent on:
    • Pharmacokinetic BE (fasted/fed design where relevant)
    • Analytical method validation and impurity control
    • Stability and dissolution consistency

Regulatory timing realities

  • Dossier quality and CMC completeness drive review speed.
  • Rework cycles tied to BE bridging, sampling design, or stability/impurity documentation can extend timelines even after initial acceptance.

How does NRDL listing and VBP procurement reshape branded revenues and generic launches?

NRDL and VBP determine whether approvals translate into commercial scale.

NRDL listing effects

  • Branded: secures reimbursed status and improves access for hospitals aligned to national reimbursement.
  • Generics: NRDL access is often the gateway to procurement volume, especially for drugs already commoditized by price competition.

VBP procurement effects

  • Brands: bid pressure and tender eligibility can reduce net price even when the brand keeps clinical position.
  • Generics: procurement offers a commercial “on-ramp” but raises operational requirements for supply assurance and low-cost manufacturing.

Commercial implication

  • A generic can be “approved” but still fail commercially if it misses procurement eligibility, cannot match price requirements, or cannot supply volume reliably.

What patents protect China branded drugs, and how do Chinese IP and drug exclusivity interact?

Patent risk is a major gating factor for generic entry even when NMPA approval is possible. Enforcement and litigation practices have evolved, with courts and administrative systems increasingly engaged in IP-related disputes.

Patent categories relevant to market exclusivity and generic challenge

  • Compound patents: active ingredient structure, stereochemistry, salts, polymorphs
  • Composition of matter: fixed-dose combinations, dosage forms, formulations
  • Method-of-use: specific indications or dosing regimens
  • Manufacturing and process patents: synthesis routes, crystallization controls, formulation manufacturing
  • Polymorph and solid-state patents: key for generics if the innovator claims specific polymorphic forms

Regulatory linkage to patent disputes

  • China has mechanisms that can delay generic commercialization when patents are asserted.
  • Generic applicants face:
    • patent landscape complexity across jurisdictions
    • risk of injunctions or enforcement actions
    • settlement-driven exclusivity extensions

When does China branded and generic exclusivity end, and what triggers entry risk?

Exclusivity timelines in China combine regulatory exclusivity concepts, patent terms, and procurement economics. Entry risk increases when multiple barriers fall away, not when any single date passes.

Common end-of-exclusivity triggers

  • Patent expiry (compound or composition of matter)
  • Lapse or invalidation of asserted patents
  • End of regulatory data exclusivity where applicable
  • Settlement agreements reaching term end
  • NRDL repricing cycles that reduce barriers to substitutes

Featured-snippet answer

Market entry risk peaks when the last blocking patent (compound or formulation) expires or is cleared and the generic can secure procurement eligibility at an economically viable price point.

Which formulations are protected by patents in China, and what dosage forms are most vulnerable?

Formulation and solid-state patents often determine whether generics can launch promptly after compound expiry.

High-risk formulation IP areas

  • Controlled-release and sustained-release matrices
  • Fixed-dose combinations (FDCs) with specific ratios
  • Specific polymorph/crystal forms
  • Co-crystals and solvates claims
  • Stability-driven formulation compositions tied to impurity profiles

Dosage forms that affect generic feasibility

  • Oral solid forms with proprietary crystal form or dissolution control can require extensive development and analytic comparability.
  • Complex inhalation or biologic delivery systems face heavier CMC barriers, increasing time-to-market.

What generic entry risks exist for China when innovators file patent assertions?

Generic launch risk is driven by patent coverage breadth, enforcement likelihood, and settlement behavior.

Practical entry-risk channels

  • Blocking patents across multiple families: compound + solid state + formulation + method-of-use
  • Multiple asserted jurisdictions and enforcement forums
  • High-cost BE and CMC bridging for alternative crystalline forms
  • Supply chain constraints for procurement at lowest prices

Commercial impact

Even with NMPA approval, post-approval commercialization can be delayed by enforcement and negotiated entry carve-outs.

How strong is the patent estate for China generics challengers, and how many patents typically block a launch?

Blocking estates often include several overlapping IP layers. The number of asserted patents can vary widely by molecule vintage, but the most common pattern is multi-dimensional coverage.

Typical estate shape

  • 1 compound family (often broad)
  • 1–3 solid-state or polymorph/form
  • 1–3 formulation or delivery system patents
  • 1–2 method-of-use or dosing regimen patents
  • additional process patents if manufacturing is non-trivial

How companies use this

  • Innovators negotiate settlements with carve-outs tied to:
    • launch time
    • product-specific scope
    • manufacturing or formulation constraints

What patent litigation affects China generic launches, and how do settlements change timing?

Patent disputes can delay commercialization through court outcomes or negotiated agreements.

Settlement patterns that shift launch dates

  • Agreed launch deferrals for specific strengths or formulations
  • Narrower claim scopes limiting generic to certain forms
  • Supply and distribution terms that limit competitive substitution
  • Non-infringement admissions paired with modified product design

Commercial outcome

Settlements often trade litigation uncertainty for predictable timing, but can raise entry barriers if they require product changes.

What is the Orange Book status of drugs in China, and what replaces it for patent linkage?

China’s system differs from the US Orange Book. Patent status is managed through Chinese regulatory and legal frameworks rather than an identical Orange Book listing mechanism.

Regulatory linkage equivalent (operational view)

  • Patent assertions and dispute resolution affect generics’ commercialization even if NMPA review proceeds on a technical basis.
  • Market access timing hinges on whether a generic can enter procurement without triggering enforcement.

(This section is intentionally framework-focused rather than listing US-style Orange Book entries, which are not the controlling model for China.)

How do China regulatory submissions differ for branded lifecycle management vs generic maintenance?

Branded lifecycle management and generic maintenance differ in their core regulatory objectives.

Branded lifecycle management priorities

  • New indications aligned with NRDL evidence standards
  • Dosage form changes that preserve IP while expanding patient reach
  • CMC optimization that avoids narrowing protection coverage

Generic maintenance priorities

  • BE and analytical equivalence
  • CMC consistency and comparability
  • Post-approval variation filings that do not trigger re-review or supply disruptions

Which companies are positioned to benefit from China’s branded and generic regulatory opportunities?

The opportunity set is concentrated in organizations that can execute on three simultaneous fronts: dossier excellence, manufacturing readiness, and IP-aware product design.

Who wins under current conditions

  • Innovative sponsors with NRDL-capable clinical packages and pricing strategy
  • Generic developers with strong CMC systems and BE execution discipline
  • Contract development and manufacturing organizations (CDMOs) that can support scale-up to procurement volumes

Competitive dynamics

  • Procurement winners are typically those with best-in-class cost-to-quality performance.
  • Brands often remain strong where:
    • alternatives are clinically non-substitutable
    • formularies preserve clinician preference
    • reimbursement rules lag behind substitutes

How does China’s biosimilar environment change branded vs generic competitive balance?

Biosimilars introduce a different risk profile than small-molecule generics, with higher CMC complexity and longer development cycles.

Biosimilar key bottlenecks

  • Analytical similarity and functional testing
  • Clinical bridging strategies
  • Manufacturing comparability across cell line and process changes

Commercial implications for brands

  • As biosimilars expand, pricing pressure increases and switching accelerates where payers support interchangeability.
  • Patent disputes remain common, but formulation-like IP translates into manufacturing and process claims.

What commercial metrics matter most for branded and generic planning in China?

Commercial planning in China depends on regulatory-to-commercial conversion.

Branded metrics

  • NRDL status and subsequent price negotiation outcomes
  • Tender participation and winning bid history
  • Channel inventory and hospital conversion rates
  • Net price trajectory under VBP cycles

Generic metrics

  • BE success and speed to approval
  • CMC batch readiness for scale
  • Procurement win probability and supply allocation commitments
  • Patent clearance strategy affecting launch timing

How to map regulatory and IP barriers to a China launch plan for a generic or brand lifecycle product

A robust China market entry plan should integrate regulatory sequencing with IP risk management and CMC execution.

Operational sequence that typically reduces launch failure risk

  1. Patent landscape mapping across compound, solid state, formulation, method-of-use
  2. BE strategy design aligned to NMPA expectations and product form
  3. CMC development and stability plan that supports commercial-scale batch consistency
  4. Infringement-risk mitigation via formulation or process design where feasible
  5. Procurement readiness with supply assurance and cost targeting

Key Takeaways

  • China branded performance is increasingly shaped by VBP and NRDL-driven access, with pricing pressure compressing revenue faster than volume.
  • Generic success depends on BE and CMC execution that satisfies NMPA expectations plus the ability to clear patent and enforcement barriers tied to commercialization timing.
  • Formulation and solid-state patents are the main launch blockers after compound expiry, affecting dosage form selection, crystallinity strategy, and BE design.
  • Regulatory approval does not guarantee commercialization in China; tender eligibility and post-approval patent disputes are decisive.
  • The biggest opportunities sit with sponsors that can integrate regulatory excellence, manufacturing scale-up, and patent-aware product design.

FAQs

  1. What most determines whether a generic approved in China gains procurement volume?
    Procurement eligibility, supply readiness, bid economics, and patent/enforcement clearance timing.

  2. Which NMPA submission components most frequently delay generic approvals?
    BE study design assumptions, BE bridging justifications, and CMC completeness for stability, impurities, and dissolution.

  3. How do solid-state form differences affect China generic development?
    They can force new formulation and analytical method work to match dissolution/impurity profiles and demonstrate equivalence.

  4. Do patent disputes in China mainly delay NMPA approval or commercialization?
    They primarily affect commercialization and market access timing even when technical regulatory review proceeds.

  5. What’s the biggest strategic difference between small-molecule generics and biosimilars in China?
    Biosimilars have higher CMC and analytical similarity burden and typically face longer development and more manufacturing comparability scrutiny.

References

  1. NMPA. (n.d.). Center for Drug Evaluation (CDE) and drug registration framework resources. National Medical Products Administration.
  2. NMPA. (n.d.). Technical guidelines and regulatory policies for generic drug approval and BE requirements. National Medical Products Administration.
  3. State Council of the PRC and NMPA materials. (n.d.). National reimbursement and centralized procurement policy documents related to drug access.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links